Your browser doesn't support javascript.
loading
Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CLpro.
Ma, Ling; Li, Quanjie; Xie, Yongli; Yi, Dongrong; Guo, Saisai; Guo, Fei; Wang, Jing; Yang, Long; Cen, Shan.
Affiliation
  • Ma L; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China.
  • Li Q; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China.
  • Xie Y; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China.
  • Jianyuan Zhao; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China.
  • Yi D; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China.
  • Guo S; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China.
  • Guo F; Institute of Pathogen Biology, Chinese Academy of Medical Science, Beijing, China.
  • Wang J; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China. Electronic address: jingwang@imb.pumc.edu.cn.
  • Yang L; School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. Electronic address: longyangrich@hotmail.com.
  • Cen S; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China. Electronic address: shancen@imb.pumc.edu.cn.
Antiviral Res ; 207: 105419, 2022 Nov.
Article in En | MEDLINE | ID: mdl-36155070
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / Hepatitis C / HIV Protease Inhibitors / COVID-19 Drug Treatment Type of study: Prognostic_studies Limits: Humans Language: En Journal: Antiviral Res Year: 2022 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / Hepatitis C / HIV Protease Inhibitors / COVID-19 Drug Treatment Type of study: Prognostic_studies Limits: Humans Language: En Journal: Antiviral Res Year: 2022 Document type: Article